Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

ESSENTIALS: Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in biopharmaceutical products are an immunogenic risk factor. Aggregates were identified in recombinant full‐length factor VIII products. Aggregates in recombinant factor VIII products are...

Descripción completa

Detalles Bibliográficos
Autores principales: Healey, J. F., Parker, E. T., Lollar, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
COAGULATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809250/
https://www.ncbi.nlm.nih.gov/pubmed/29197156
http://dx.doi.org/10.1111/jth.13917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809250/
https://www.ncbi.nlm.nih.gov/pubmed/29197156
http://dx.doi.org/10.1111/jth.13917

Ejemplares similares